MiR-21 controls in situ expansion of CCR6 + regulatory T cells through PTEN/AKT pathway in breast cancer

Immunology and Cell Biology

Volumn 93, Issue 8, 2015, Pages 753-764

  Hu, Yan ^a   Wang, Chunhong ^b   Li, Yongju ^a   Zhao, Juanjuan ^a   Chen, Chao ^a   Zhou, Ya ^a   Tao, Yijin ^a   Guo, Mengmeng ^a   Qin, Nalin ^a   Ren, Tao ^b   Wen, Zhenke ^c,d   Xu, Lin ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD3 ANTIBODY; GAMMA INTERFERON; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; T LYMPHOCYTE RECEPTOR; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR6; MICRORNA; MIRN21 MICRORNA, HUMAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PATIENT; CCR6 REGULATORY T CELL; CD8+ T LYMPHOCYTE; CELL DEATH; CELL EXPANSION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE CONTROL; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; CELL LINE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; BIOMARKERS; BREAST NEOPLASMS; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICRORNAS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, CCR6; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84941878945     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.37     Document Type: Article

References (40)

1. Fukuyama Y, Tokuhara D, Sekine S, Aso K, Kataoka K, Davydova J et al. Potential roles of CCR5(+) CCR6(+) dendritic cells induced by nasal ovalbumin plus Flt3 ligand expressing adenovirus for mucosal IgA responses. PLoS ONE 2013; 8: e60453.
2. Hammerich L, Bangen JM, Govaere O, Zimmermann HW, Gassler N, Huss S et al. Chemokine receptor CCR6-dependent accumulation of T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 2014; 59: 630-642.
3. Mercer F, Khaitan A, Kozhaya L, Aberg JA, Unutmaz D. Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors. J Immunol 2014; 193: 1047-1054.
4. Kitamura K, Farber JM, Kelsall BL. CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype. J Immunol 2010; 185: 3295-3304.
5. Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rotzschke O, Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T cell subset. Blood 2005; 105: 2877-2886.
6. Lamprecht B, Kreher S, Anagnostopoulos I, Johrens K, Monteleone G, Jundt F et al. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 2008; 112: 3339-3347.
7. Xu L, Xu W, Qiu S, Xiong S. Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol 2010; 135: 466-475.
8. Xu L, Xu W, Wen Z, Xiong S. In situ prior proliferation of CD4+ CCR6+ regulatory T cells facilitated by TGF-secreting DCs is crucial for their enrichment and suppression in tumor immunity. PLoS ONE 2011; 6: e20282.
9. Xu LF, Wu ZP, Chen Y, Zhu QS, Hamidi S, Navab R. MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China. PLoS ONE 2014; 9: e103698.
10. Hutcheson R, Chaplin J, Hutcheson B, Borthwick F, Proctor S, Gebb S et al. miR-21 normalizes vascular smooth muscle proliferation and improves coronary collateral growth in metabolic syndrome. FASEB J 2014; 28: 4088-4099.
11. Echevarria-Vargas IM, Valiyeva F, Vivas-Mejia PE. Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS ONE 2014; 9: e97094.
12. Eto K, Iwatsuki M, Watanabe M, Ida S, Ishimoto T, Iwagami S et al. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol 2014; 21: 343-350.
13. Smigielska-Czepiel K, van den Berg A, Jellema P, Slezak-Prochazka I, Maat H, van den Bos H et al. Dual role of miR-21 in CD4+ T-cells: activation-induced miR-21 supports survival of memory T-cells and regulates CCR7 expression in naive T-cells. PLoS ONE 2013; 8: e76217.
14. Kroesen BJ, Teteloshvili N, Smigielska-Czepiel K, Brouwer E, Boots AM, van den Berg A et al. Immuno-miRs: critical regulators of T-cell development, function and ageing. Immunology 2014; 144: 1-10.
15. Sommers CL, Rouquette-Jazdanian AK, Robles AI, Kortum RL, Merrill RK, Li W et al. miRNA signature of mouse helper T cell hyper-proliferation. PLoS ONE 2013; 8: e66709.
16. Garchow BG, BartulosEncinas O, Leung YT, Tsao PY, Eisenberg RA, Caricchio R et al. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med 2011; 3: 605-615.
17. Khan AA, Penny LA, Yuzefpolskiy Y, Sarkar S, Kalia V. MicroRNA-17~ 92 regulates effector and memory CD8 T-cell fates by modulating proliferation in response to infections. Blood 2013; 121: 4473-4483.
18. Wong GW, Knowles GC, Mak TW, Ferrando AA, Zuniga-Pflucker JC. HES1 opposes a PTEN-dependent check on survival, differentiation, and proliferation of TCR-selected mouse thymocytes. Blood 2012; 120: 1439-1448.
19. Damania P, Sen B, Dar SB, Kumar S, Kumari A, Gupta E et al. Hepatitis B virus induces cell proliferation via HBx-induced microRNA-21 in hepatocellular carcinoma by targeting programmed cell death protein4 (PDCD4) and phosphatase and tensin homologue (PTEN). PLoS ONE 2014; 9: e91745.
20. Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008; 28: 870-880.
21. Tosello V, Odunsi K, Souleimanian NE, Lele S, Shrikant P, Old LJ et al. Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. Clin Immunol 2008; 126: 291-302.
22. Gunnlaugsdottir B, Maggadottir SM, Skaftadottir I, Ludviksson BR. The ex vivo induction of human CD103+ CD25hi Foxp3+ CD4+ and CD8+ Tregs is IL-2 and TGF-1 dependent. Scand J Immunol 2013; 77: 125-134.
23. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res 2010; 107: 57-117.
24. Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 2009; 182: 2578-2582.
25. Qin A, Wen Z, Zhou Y, Li Y, Li Y, Luo J et al. MicroRNA-126 regulates the induction and function of CD4(+) Foxp3(+) regulatory T cells through PI3K/AKT pathway. J Cell Mol Med 2013; 17: 252-264.
26. Sethi A, Kulkarni N, Sonar S, Lal G. Role of miRNAs in CD4 T cell plasticity during inflammation and tolerance. Front Genet 2013; 4: 8.
27. Smigiel KS, Richards E, Srivastava S, Thomas KR, Dudda JC, Klonowski KD et al. CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. J Exp Med 2014; 211: 121.
28. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S et al. TGF-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 2012; 22: 291-303.
29. Zhao J, Li Y, Hu Y, Chen C, Zhou Y, Tao Y et al. MicroRNAs expression profile in CCR6 (+) regulatory T cells. PeerJ 2014; 2: e575.
30. Yan NB, Zhao YY, Li XL, Yong Z. MicroRNA-21 accelerates hepatocyte proliferation in vitro via PI3K/Akt signaling by targeting PTEN. Biochem Biophys Res Commun 2014; 443: 802-807.
31. Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol 2013; 191: 1677-1685.
32. Pan W, Zhu S, Yuan M, Cui H, Wang L, Luo X et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 2010; 184: 6773-6781.
33. Walsh PT, Buckler JL, Zhang J, Gelman AE, Dalton NM, Taylor DK et al. PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J Clin Invest 2006; 116: 2521-2531.
34. Wang JY, Gao YB, Zhang N, Zou DW, Wang P, Zhu ZY et al. miR-21 overexpression enhances TGF-1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol 2014; 392: 163-172.
35. Jiang Y, Chen X, Tian W, Yin X, Wang J, Yang H. The role of TGF-1-miR-21-ROS pathway in bystander responses induced by irradiated non-small-cell lung cancer cells. Br J Cancer 2014; 111: 772-780.
36. Luo CT, Li MO. Transcriptional control of regulatory T cell development and function. Trends Immunol 2013; 34: 531-539.
37. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30: 531-564.
38. Rouas R, Fayyad-Kazan H, El Zein N, Lewalle P, Rothe F, Simion A et al. Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol 2009; 39: 1608-1618.
39. Asanuma S, Tanaka J, Sugita J, Kosugi M, Shiratori S, Wakasa K et al. Expansion of CD4(+)CD25 (+) regulatory T cells from cord blood CD4(+) cells using the common-chain cytokines (IL-2 and IL-15) and rapamycin. Ann Hematol 2011; 90: 617-624.
40. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3 + regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111: 453-462.